Navigation Links
Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
Date:3/17/2010

">David Sidransky, Chairman of the Board of Directors of Champions Biotechnology, Inc., commented, "This past quarter, although we saw reduced revenues from our Personalized Oncology business, we continued to see solid performance from our Preclinical eValuation business. Having made strong progress in building the integrity of our platform for the Preclinical eValuation business, we can now more fully implement our primary objective to in-license a pipeline of high potential oncology drugs and compounds. The Company progress to date is evidenced by the following:

  1. The Company's quarterly Preclinical eValuation revenues increased 402% year over year.
  2. Champions entered into an exclusive Option Agreement with a leading Canadian research organization to review a cancer drug candidate.  This brings our total number of products owned, licensed or under option agreements to four.
  3. Champion's Preclinical eValuation business expanded and initiated new contracts with several major Biotechnology and Pharmaceutical companies.
  4. Champions has received signed subscription agreements totaling $3.0 million to date of which $2.2 million has been received in our private placement to accredited investors."

For more information regarding Champions Biotechnology's business and recent news, please visit www.championsbiotechnology.com


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... Jolla, CA (PRWEB) August 19, 2014 ... toll Parkinson’s disease can take on an individual. ... extremities, decreased facial expression, problems swallowing and severe depression. ... to the dying off of dopamine producing neurons of ... themselves from a disease that slowly and progressively gets ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... Vivo Ventures, a venture,capital firm specializing in life ... firm as an Executive in Residence. With his,extensive business ... portfolio companies while enhancing the firm,s presence in,Asia. ... what he will be able to,bring to Vivo," said ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that ... U.K. Phase Ia/Ib combination,REOLYSIN(R)/radiation clinical trial for ... to be presented today at the AACR-NCI-EORTC,International ... in,San Francisco. The conference runs from October ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... letter of approval from the U.K. Medicines ... Clinical Trial Application (CTA) to begin,a clinical ... with cyclophosphamide, a chemotherapeutic agent as well ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A*STAR scientists from the Institute of Molecular and Cell Biology ... 100 years, by constructing stable haploid strains of ... This discovery, jointly made by two teams of scientists led ... Berman of the University of Minnesota, will enable scientists to ...
... Chronicle of Higher Education , the National Institutes ... in the review of grant applications. (Found at: ... professor of biomedical engineering at the Virginia ... Engineering and Sciences , and seven of his ...
... the journal Science , today announces the 53 ... Technology Visualization Challenge, a highly competitive contest jointly sponsored ... magazine is published by the American Association for the ... than 200 entries from 18 countries, including entries from ...
Cached Biology News:A*STAR scientists solve century-old mystery by finding stable haploid strains of Candida albicans 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 3Winners of 10th annual International Science & Technology Visualization Challenge announced 2Winners of 10th annual International Science & Technology Visualization Challenge announced 3
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Request Info...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Green Standard is fluorescein....
Biology Products: